The development of the skeletal system, as well as its repair, are dependent on the differentiation of both chondrocytes and osteoblasts from their common progenitor, the mesenchymal stem cell (MSC). There are two processes from which bone is formed. During intramembranous osteogenesis, bone is formed directly from MSC differentiation to osteoblasts. This process gives rise to flat bones, such as those of the skull and clavicle. In contrast, endochondral osteogensis requires MSC differentiation to chondrocytes and the formation of a cartilage template, which is followed by ossification by osteoblasts. This process is responsible for the formation of the long bones of the skeleton, and remains active in the growth plates of growing bones (reviewed in Refs 1, 2). Bone fracture repair recapitulates the events of skeletogenesis and is, therefore, used as an experimental model of bone formation (Ref. 3) . These processes are regulated by paracrine actions between osteoblasts and chondrocytes, and thus, proper skeletogenesis requires precise control over the differential differentiation of the MSC to these lineages. Failure of chondrocyte or osteoblast precursors to proliferate and differentiate leads to various types of skeletal dysplasias, depending on the pathway involved (reviewed in Ref. 4) .
Skeletogenesis: an overview The osteochondroprogenitor
The majority of what is known about MSC differentiation along the skeletal lineage comes from embryology. Endochondral and intramembranous skeletogenesis begins with the proliferation and migration of mesenchymal cells to form condensations. These condensations are characterised as tightly packed cells that express specific condensation markers, and will determine the position, shape and size of the skeletal elements (Ref. 5) . The transforming growth factor-β and Hox family of molecules, derived from the epithelium, have been implicated in directing the formation of condensations. These molecules, along with the cell-cell and cell-matrix interactions that result from the compact nature of these cells, are thought to trigger MSC differentiation (Refs 5, 6) .
As the osteochondroprogenitor is multipotent, lineage fate decisions must be made and maintained. The transcription factor runt-related transcription factor 2 (Runx2) is believed to determine osteoblast versus chondrocyte differentiation. Various studies have shown that upregulation of Runx2 induces osteoblastic differentiation, whereas its persistent expression in chondrocytes causes premature maturation and mineralisation (Ref. 7) . Runx2 is expressed in prechondrogenic and preosteogenic condensations, but during early embryogenesis, outside signals regulate its expression (Ref. 5) . Homeobox protein A2 (Hoxa-2) and Wnt (wingless-type mouse mammary tumor virus (MMTV) integration site) signalling have both been implicated in this process. Through specific inactivation in the developing limbs of mice, β-catenin, a downstream effector protein of Wnt signalling, was found to be essential to bone development as these embryos had impaired osteoblast differentiation (Ref. 8) . Also, it was found that if β-catenin is activated, it upregulates Runx2 expression and MSCs differentiate to osteoblasts, rather than chondrocytes (Refs 8, 9, 10). These results implicate β-catenin in the determination of osteo-versus chondrogenesis.
Chondrogenesis
Chondrocytes are the first skeletal cells to arise, and their differentiation depends on the expression of the transcription factor sry (sex determining region Y)-box 9 (Sox9). The importance of Sox9 was discovered when a genetic mutation in humans was found to be the cause of campomelic dysplasia, characterised by severe cartilage abnormalities (Refs 11, 12 
Osteoblastogenesis
The transcription factor Runx2 is absolutely necessary for osteoblast differentiation. Runx2 knockout (KO) mice show a total absence of differentiated osteoblasts and, therefore, lack any bone (Refs 18, 19 In summary, it appears that the differentiation to chondrocytes may occur by default, when Runx2 and osteoblast differentiation are suppressed. It is also possible that signals that upregulate Sox9 are responsible for the suppression of the osteoblast differentiation programme. Figure 2 illustrates these two paths of differentiation.
Cyclic-AMP as a regulator of osteoblastogenesis and chondrogenesis
Although there are master regulators that direct MSC differentiation, various other molecules have been demonstrated to modulate the process. Here, we will focus on those that signal through cyclic-AMP (cAMP). cAMP is a ubiquitous second messenger that is synthesised from ATP by adenylyl cyclases. cAMP levels are regulated by different stimuli, one major effector being G-protein-coupled receptors. These receptors are classified either as stimulatory (Gαs) or inhibitory (Gαi) of adenylyl cyclase. Changing levels of cAMP is translated to the cell through cAMP's action on cyclic nucleotidegated ion channels, on exchange proteins known as Epacs, and on protein kinase A (PKA) (reviewed in Ref. 31) . PKA activation further perpetuates the signal by phosphorylating different target proteins. Ultimately, cellular transcription can be modified through the cAMP-dependent transcription factors CREB, cAMP response element modulator (CREM) and ATF-1 (reviewed in Refs 31, 32, 33) . cAMP is degraded by phosphodiesterases, which remove a phosphodiester bond and produce AMP. These enzymes play a major role, not only in terminating the signal, but also in regulating the amplitude and duration of the signal (Ref. 34) .
The 
Sox9 interacts with CREB binding protein (CBP) and p300 to increase its transcriptional activity. Using a Col2α1 gene promoter reporter construct in a chondrocyte cell line, as well as a Gal4-Sox9 fusion protein, it was reported that co-transfection with CBP and/or p300 increased Taken together, it appears that cAMP signalling is capable of upregulating Runx2, a master regulator of osteoblasts, and Sox9, a master regulator of chondrocytes. Since Sox9 is an inhibitor of Runx2 expression, it is possible that the sum effect of cAMP on lineage determination depends on its concentration, cellular localisation and a possible regulatory loop.
Adenosine receptors
Adenosine is a regulatory metabolite and its receptors are comprised of a family of seven transmembrane domain G protein-coupled receptors. A1 and A3 adenosine receptors (A1AR and A3AR) are coupled to Gαi and are, therefore, adenylyl cyclase inhibiting, whereas A2A and A2B adenosine receptors (A2AAR and A2BAR) are coupled to Gαs, which stimulates adenylyl cyclase and produces a cAMP signal. The A2BAR may also be coupled to Gαq, which activates phospholipase C (Ref. 
Adenosine receptors and osteoblast and chondrocyte differentiation
Only recently has the role of adenosine receptors in osteoblast differentiation been examined. In a broad sense, purinergic signalling was looked at in the context of bone, and ATP receptors (P2X and P2Y) were found to promote differentiation and proliferation in an osteoblast cell line (MC3T3-E1) (Ref. 81) . It was found that after bone injury and when exposed to hypoxic conditions, rat osteoblasts secrete ATP in the high nM to μM range (Ref. 82 Activation of the A2BAR with pharmacological agonists increased the expression of these transcription factors, as well as caused an increase in the number of mineralised nodules. Treatment with a cAMP analogue also increased the expression of Osterix, suggesting that cAMP may be the mechanism of action for A2BAR effect on differentiation. In addition, the A2BAR KO mouse had mild osteopenia, and a delayed or impaired bone fracture healing response (Ref. 54) .
There have been few reports on the effect of the cAMP inhibitory adenosine receptors, A1AR and A3AR on osteoblast differentiation. A role for adenosine receptors in chondrocyte differentiation has not yet been examined and/ or reported. However, as A1-and A2-type ARs are known to be expressed in MSCs (Refs 56, 79), and given the published influence of cAMP on Sox9 (as described above), it is likely that a role for these receptors on the differentiation of this lineage will be found.
Inflammation and osteoblast and chondrocyte differentiation: implication for adenosine receptors
Inflammation plays a significant role in bone development (reviewed in Ref. 85 ) and regeneration (reviewed in Ref. 86) . Although adenosine receptor signalling through cAMP has the potential to directly influence osteo-or chondrogenesis, cAMP signalling through these receptors can also affect the level of inflammatory cytokines systemically or at the cellular level (reviewed in Ref. 87 ). Here, we will focus on a brief survey of the effects of inflammatory processes on bone cell differentiation, followed by a summary of A2-type adenosine receptors effects on inflammation and its potential influence on bone cell lineages.
The effect of inflammation on osteoblast differentiation
The effect of inflammation on the skeletal system, including osteoblast differentiation, has been well studied, particularly the effects of tumour necrosis factor-α (TNF-α) (reviewed in Ref. . Taken together, it is then quite possible that adenosine receptor modulation of inflammatory cytokines affects directly or indirectly the process of MSC differentiation into bone cell lineages. Figure 3 illustrates a proposed mechanism of A2BAR effects on osteoblast differentiation involving CREB and/or TNF-α.
Adenosine receptors and inflammation
One of the principal attributes of adenosine and its receptors is its pro-or anti-inflammatory effects, most of which are mediated via cAMP signalling. The concentration of our laboratory has been the A2BAR, and thus will be the focus of this section. Both pro-and anti-inflammatory effects of the A2BAR have been described, and these depend on the cell type and stimulus. In addition, these effects have been ascribed either protective or deleterious roles, depending on the context, e.g. chronic versus acute pathology (reviewed in Ref. 103) . Complete KO of the A2BAR gene results in a slight systemic inflammation, as KO animals have elevated plasma levels of TNF-α at baseline, and elevated levels of TNF-α and IL-6 expression in macrophages (Ref. 104 ). These differences in cytokine levels are exacerbated upon stress or injury. Treatment of A2BAR KO mice with lipopolysaccharide causes an exceptional increase in TNF-α and IL-6 plasma levels and in macrophage expression, relative to WT mice (Ref. 104) .
The ability of the A2BAR to dampen inflammation in response to stimuli highlights its protective role during stress or injury. The importance of this role is confirmed by findings that the expression of the receptor is also induced by these stimuli. Treatment of vascular smooth muscle cells with TNF-α causes an upregulation of A2BAR expression. Further, this increase was shown to be mediated by NADPH oxidase 4 (Nox4) signalling (Ref. 105) .
As NFκB has an important role in the regulation of cellular inflammation it has been a target of investigation in relation to A2BAR signalling. Recently, we found the A2BAR to directly bind p105, an inhibitor of NFκB, stabilising it and preventing its degradation (Ref. 106) . This mechanism helps explain the inflammatory phenotype in the A2BAR KO mice and the Proposed mechanism for A2BAR action on osteoblast differentiation. Activation of the mesenchymal stem cell A2BAR triggers cAMP signalling, which may modulate the expression and/or activity of a key osteoblast transcription factor, Runx2, and promote osteoblast differentiation. A2BAR activation also decreases tumour necrosis factor-α level, which has an inhibitory effect on osteoblast differentiation. ability of the A2BAR to downregulate inflammation.
Considering the above described effects of TNF-α, IL-1 and IL-6 on bone cell differentiation, it is possible that some of the A2BAR's recently described protective effect in a mouse bone injury model (Ref. 54 ) is related to changes in cytokine levels.
Adenosine receptors as therapeutics for osteoporosis, skeletal injury and arthritis . In our study, we also found that A2BAR KO mice have changes in bone fracture healing with decreased callus bone formation and an apparent delay in healing (Ref. 54) . Although the anti-inflammatory effects of adenosine likely have an important role in improving skeletal injury repair, we contend that adenosine, through the A2BAR, may also improve healing by promoting osteoblast differentiation (Ref. 54) . Therefore, agonism of the A2-type ARs may be useful as a therapeutic for osteoporosis and bone injury.
As caffeine is an antagonist of adenosine receptors, its effects on bone may be relevant here. In epidemiological studies of risk factors for osteoporosis in humans, caffeine was either found to be negatively associated with (Refs 109, 110) or not associated with bone mineral density ( Refs 111, 112, 113, 114) . It is possible that effects of caffeine are confounded by factors such as age, oestrogen levels and calcium intake. In a study of over 3000 individuals using the Framingham Cohort, it was found that caffeine intake was associated with a higher relative risk of hip fracture (Ref. 115) . In experimental animals, caffeine has been shown to inhibit bone formation. When demineralised bone particles were implanted subcutaneously, rats that were treated with caffeine had decreased chondrogenesis and decreased mineralisation (Ref. 116 
Conclusions
There are a multitude of signalling molecules and pathways that converge during chondrocyte and osteoblast differentiation. The coordination of the spatial and temporal pattern of these molecules is necessary for correct bone formation.
Through exploration of the downstream signalling of G-protein-coupled receptors, cAMP was found to be an important component of the signalling pathways needed for full differentiation of MSCs along the skeletal lineage. Continued investigation into the contribution of these receptors, adenosine receptors among them, to bone homoeostasis and regeneration could lead to important discoveries with clinically therapeutic implications.
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